Avalo Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q1 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Avalo Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2019 to Q4 2024.
  • Avalo Therapeutics, Inc. Costs and Expenses for the quarter ending December 31, 2024 was $13.5M, a 64.1% increase year-over-year.
  • Avalo Therapeutics, Inc. Costs and Expenses for the twelve months ending December 31, 2024 was $69M, a 136% increase year-over-year.
  • Avalo Therapeutics, Inc. annual Costs and Expenses for 2024 was $69M, a 136% increase from 2023.
  • Avalo Therapeutics, Inc. annual Costs and Expenses for 2023 was $29.3M, a 47.2% decline from 2022.
  • Avalo Therapeutics, Inc. annual Costs and Expenses for 2022 was $55.5M, a 36.6% decline from 2021.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $69M $13.5M +$5.27M +64.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-20
Q3 2024 $63.7M $13.1M +$9.12M +229% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $54.6M $9.58M +$1.78M +22.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $52.8M $32.8M +$23.5M +254% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-07-11
Q4 2023 $29.3M $8.23M -$1.52M -15.6% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-20
Q3 2023 $30.8M $3.99M -$6.87M -63.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $37.7M $7.79M -$5.07M -39.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $42.7M $9.27M -$12.8M -57.9% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-07-11
Q4 2022 $55.5M $9.75M -$8.43M -46.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $63.9M $10.9M -$6.96M -39.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $70.9M $12.9M -$7.62M -37.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $78.5M $22M -$9.03M -29.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $87.5M $18.2M +$348K +1.95% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 $87.2M $17.8M +$3.43M +23.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $83.8M $20.5M +$7.33M +55.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $76.4M $31.1M -$3.11M -9.11% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $79.5M $17.8M +$11.5M +183% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 $68M $14.4M +$9.33M +184% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $58.7M $13.2M +$9.21M +234% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-02
Q1 2020 $49.5M $34.2M +$26.6M +351% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $22.9M $6.3M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 $5.06M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $3.94M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $7.58M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.